Saturday, March 27, 2010

DePuy ASR Hip Replacement Failure Law Firm Alliance Formed

Two law firms that have extensive experience representing patients across the nation in failed hip and knee replacement cases have formed a coalition to represent patients with failed DePuy ASR (Articular Surface Replacement) XL metal-on-metal hip replacement systems.

Sarasota, FL (PRWEB) March 28, 2010 -- The Maglio Christopher Toale & Pitts Law Firm, based out of Sarasota, Florida and the Nash & Franciskato Law Firm, based out of Kansas City, Missouri have formed a consortium to jointly represent patients with failed DePuy ASR (Articular Surface Replacement) XL metal-on-metal hip replacement systems. Both law firms have focused on representing patients across the nation in failed hip and knee replacement cases for many years. Both law firms also have extensive experience in representing patients in litigation against both DePuy Orthopaedics and Johnson & Johnson's prior orthopedics subsidiary, Johnson & Johnson Orthopaedics. Clients of the Alliance will be jointly represented by both member law firms who will work together on behalf of each client.

Depuy Orthopedics advertised many advantages of the ASR XL hip replacement system over both conventional hip replacements and over hip resurfacing. DePuy described the ASR XL as a "high performance hip replacement". Unfortunately, the ASR hip replacement did not perform as promised. As a result, in the fall of 2009, DePuy decided to cease sales of the ASR XL Acetabular Head System and early in 2010 DePuy pulled the remaining ASR hip replacements from inventory. DePuy insists that their decision was not a "recall", but instead a decision based on declining sales. The declining sales were largely attributable to problems that orthopedic surgeons were having with the ASR hip replacement, including implant failure necessitating revision.

The Alliance can be contacted toll free at 877-284-6600.

See Also:

[Via Legal / Law]

medications for depression | buy kamagra online | cialis super active+ 20mg

No comments: